Physician profile
Heather Armand
NPI 1740419357
$2,384.81
in general payments reported to CMS, 2019-2025
24 companies · $550 in 2025
The $550 reported for 2025 was more than what 86% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $700 · 2022: $435 · 2023: $301 · 2024: $398 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.68 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.76 | 2021-2025 | |
| Astellas Pharma US INC | $276.12 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $215.74 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Myovant Sciences INC. | $194.99 | 2021-2022 | |
| Daiichi Sankyo INC. | $114.94 | 2022-2024 | Injectafer |
| Hologic Sales and Service, LLC | $83.16 | 2021-2025 | Aptima |
| Sumitomo Pharma America, INC. | $61.64 | 2025 | Myfembree |
| Exact Sciences Corporation | $52.16 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $42.77 | 2022-2023 | Pediarix, Shingrix, Bexsero |
| Pfizer INC. | $38.62 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $37.43 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.26 | 2024-2025 | |
| Amgen INC. | $34.73 | 2024-2025 | Otezla, Repatha, Otezla |
| Therapeuticsmd, INC. | $34.66 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $32.64 | 2023-2024 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $24.17 | 2024 | |
| Agile Therapeutics, INC. | $23.60 | 2021 | |
| Scynexis, INC. | $22.52 | 2022 | |
| Exeltis, USA INC. | $20.46 | 2024 | Slynd |
| Astrazeneca Pharmaceuticals LP | $20.29 | 2024 | |
| Collegium Pharmaceutical, INC. | $19.98 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $19.61 | 2023 | |
| Lilly USA, LLC | $17.88 | 2025 | Zepbound |
| Organon LLC | $12.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Armand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.